New chemo delivery method aims to shrink untreatable colon tumors
NCT ID NCT07333053
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a procedure called transarterial infusion chemotherapy (TAIC) for people with colorectal cancer that cannot be removed by surgery. Instead of giving chemo through a vein, TAIC delivers it directly to the tumor's blood supply, which may boost effectiveness and reduce side effects. The trial will enroll 30 participants and compare TAIC plus targeted drugs to standard intravenous chemo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
chemotherapy (FOLFOX) plus either cetuximab or bevacizumab
What this could lead to
If it works, this could offer a more effective and less toxic treatment option for people with colorectal cancer that cannot be removed by surgery.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The procedure is invasive and carries risks like bleeding or infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guang'anmen Hospital, China Academy of Chinese Medical Sciences
RECRUITINGXicheng, Beijing Municipality, 100053, China
Contact Email: •••••@•••••
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••